You are here: Home: CACU 1 | 2007: Clifford Hudis, MD
PUBLICATIONS DISCUSSED BY CLIFFORD HUDIS, MD
Dang C et al. Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu
overexpressed/amplified breast cancer (BCA). San Antonio Breast Cancer Symposium
2006;Abstract 2101.
Puhalla S et al. Phase II randomized adjuvant trial of dose-dense docetaxel (DOC)
before or after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast
cancer. San Antonio Breast Cancer Symposium 2006;Abstract 2104.
Shayne M et al. Dose intensity and hematologic toxicity in older breast cancer patients
receiving systemic chemotherapy. San Antonio Breast Cancer Symposium
2006;Abstract 6078.
Lyman GH et al. Prospective validation of a risk model for first cycle neutropenic
complications in early-stage breast cancer patients receiving adjuvant chemotherapy.
San Antonio Breast Cancer Symposium 2006;Abstract 6083.
Gradishar W et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3w
solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC).
San Antonio Breast Cancer Symposium 2006;Abstract 46.
Link JS et al. Bevacizumab (Avastin) and albumin bound paclitaxel (Abraxane) treatment
in metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 1095.
Schwartzberg LS et al. Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) +
capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC): Interim
results. San Antonio Breast Cancer Symposium 2006;Abstract 1096.
Traina TA et al. Optimizing chemotherapy administration: A phase I study of biweekly
capecitabine dose and schedule based on Norton-Simon mathematical modeling.
San Antonio Breast Cancer Symposium 2006;Abstract 6077.
Wagner LI et al. Health-related quality of life among patients with metastatic breast
cancer receiving paclitaxel versus paclitaxel plus bevacizumab: Results from the
Eastern Cooperative Oncology Group (ECOG) study E2100. San Antonio Breast Cancer
Symposium 2006;Abstract 5078.
Cristofanilli M et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC).
San Antonio Breast Cancer Symposium 2006;Abstract 1.
Chlebowski RT et al. Mature analysis from the Women’s Intervention Nutrition Study
(WINS) evaluating dietary fat reduction and breast cancer outcome. San Antonio Breast
Cancer Symposium 2006;Abstract 32.
|
